The development of new drugs is becoming more expensive and needs infrastructure and efficient resources so, licensing collaborations are becoming a favorable option for many global pharmaceutical companies. These licensing options help companies offset to research and development investments and bypass the cumbersome innovation and development process. As per the global data, in the pharmaceutical […]

Read More →

Globally many consider herbs and botanicals to be natural and therefore healthier and gentler than conventional drugs. Currently, 30% of prescription drugs are herbal and botanical drugs. Herbals and botanicals are used for the treatment and improvement of health and well-being. Many countries use herbal and botanical drugs traditionally for many years to generations. The […]

Read More →

Lao People’s Democratic Republic (PDR) government is giving the highest priority to the healthcare sector, and this is creating a good opportunity for foreign country manufacturers like Indian and China to export low-cost high-quality generic drugs into Laos. Lao’s is a small country with a very small market for medical, health, and other pharmaceuticals. The […]

Read More →

Most errors and technical failures in clinical trials arise due to the improper selection of clinical trial designs. The clinical trial design selection will have a strong impact on the cost and time associated with clinical trials. The expected outcomes shall be thought out and carefully addressed while designing a clinical trial. The selection of […]

Read More →

Myanmar’s pharmaceutical market size was $456 million in 2017, with a percapita pharma expenditure of $8.5 and market researchers expect to reach $656 million in 2022. Myanmar’s economy is growing continuously, and the experts predict the pharmaceutical industry to quickly grow into a $1.12 billion industry in the future. Myanmar depends on the import of […]

Read More →

The number of clinical trials in rare diseases is growing drastically from the last ten years to more than 500 compared to a few hundred clinical trials. Currently, more than 400 orphan designated drugs are commercially available, and around 1000 drugs are undergoing clinical trials. But still, the clinical trials in rare diseases present many […]

Read More →

Oncology trials are more complex than trials in any other therapeutic area. Research in oncology differs in terms of trial design, trial types, the role of a comparator, treatment outcomes, adverse event reporting, interpreting the results, and more. Developing a well-defined clinical development strategy for oncology clinical trials is crucial due to the significant costs, […]

Read More →

Do you know, according to clinicaltrials.gov, a total of 354,130 clinical trials were registered worldwide with 71,256 ongoing clinical trials as recorded on Oct-2020? The number of clinical trials is increasing year by year from 56.16k in 2017 to 60.69k in 2018. In the USA, more than 2.3+ million people participate in approximately 80,000+ clinical […]

Read More →

Clinical trials in rare diseases present more significant challenges compared to trials in more common diseases. These challenges arise due to various factors, including trial design, the limited patient population for recruitment, regulatory support, and more. However, implementing a well-defined strategy for clinical development in rare diseases can help overcome these challenges. Such a strategy […]

Read More →

Drug development is a lengthy, complex, and costly process entrenched with a high uncertainty that a drug will successfully reach the market. So for this, you need a proper drug development strategy to avoid uncertainties and complete clinical trials in time with quality data. Drug development is the process to bring a new pharmaceutical drug […]

Read More →